When Nerve Stimulation Meets the Heart: Cardiovascular Signals from Hypoglossal Nerve Stimulation for Sleep Apnea

Obstructive sleep apnea (OSA) has never been just a sleep disorder. Recurrent nighttime airway collapse drives intermittent hypoxia, sympathetic surges, and inflammatory activation that ripple outward into hypertension, arrhythmia, and cardiovascular disease more broadly. That systemic connection is exactly why a new retrospective study on hypoglossal nerve stimulation (HGNS) — a surgically implanted device that keeps the airway open by electrically activating the tongue's motor nerve — deserves attention beyond pulmonology. Before examining what that study found, it's worth understanding what HGNS actually is, who invented it, how it evolved, where it's used today, and why it cannot be replicated with a consumer electrical stimulator bought online.

What HGNS Is and Where It Came From

Hypoglossal nerve stimulation treats OSA by electrically activating the hypoglossal nerve — the nerve controlling tongue movement — in rhythm with a patient's own breathing, so the tongue is pushed forward at the moment of inhalation, preventing the airway collapse that defines OSA. The idea rests on a simple physiological insight: OSA arises largely from reduced upper airway muscle activity during sleep, so restoring that muscle tone at the right moment in the breathing cycle can keep the airway open without a mask or external pressure device. 

Early feasibility work on this concept dates to trials in the early 2010s. A 2011 study of a device from Apnex Medical implanted 21 patients with moderate-to-severe OSA who could not tolerate CPAP, and found significant reductions in apnea severity and daytime sleepiness sustained through six months. The device that ultimately reached the market and defined the field — Inspire Medical Systems' implant — was validated in the STAR clinical trial, with one-year results published in the New England Journal of Medicine in January 2014 showing significant reductions in sleep apnea events and improved quality of life, effects that were sustained over five years of follow-up. The FDA approved this device later in 2014, specifically for patients with moderate-to-severe OSA (apnea-hypopnea index 15–65) who are not obese, are 18 or older, and cannot tolerate or benefit from CPAP. 

How the Therapy Actually Works: Technique and Devices

HGNS requires a surgical implant, not a wearable gadget. The system is placed under the skin of the neck and chest through small incisions in an outpatient procedure; a sensor detects the patient's breathing pattern, and a pulse generator delivers electrical stimulation to the hypoglossal nerve synchronized precisely with inspiration, so the tongue is pushed forward only when needed rather than continuously. Patients activate the device nightly with a small handheld remote before sleep and turn it off on waking. 

Three device platforms have anchored the field: the original Apnex system used in early trials, the market-leading Inspire device — the most extensively studied, with meta-analyses showing apnea-hypopnea index reductions around 20 events/hour in the short term and roughly 16 events/hour maintained long-term — and the ImThera device, which shows similar but somewhat smaller improvements. A newer entrant, the Genio system, received FDA approval and was first used in Northern California in January 2026; it stimulates the hypoglossal nerve bilaterally rather than unilaterally, is battery-free (powered externally through an adhesive skin patch), and is notably the only HGNS device clinically proven effective even when patients sleep on their backs — a position where OSA is typically most severe. Across devices, clinical success rates run roughly 80% within the first year and remain around 73% between one and three years, with effects generally plateauing rather than continuing to improve after the first 12 months.

Global Adoption: Where HGNS Is Actually Available

HGNS is not a niche experimental therapy confined to a handful of research hospitals — it is now an established, reimbursed treatment across much of the developed world, though access and specific device availability vary considerably by country. The therapy first received regulatory approval in Europe in 2013, a year before the U.S. FDA cleared it in 2014, and has since spread to thousands of patients across multiple countries. In the United States, Inspire remains the dominant and most widely implanted system, available at accredited sleep and otolaryngology centers nationwide. In Europe, Germany has emerged as one of the most developed markets, with three different HNS systems now available and an established position paper from the German Society of Oto-Rhino-Laryngology guiding patient selection and interdisciplinary aftercare. France more recently formalized HGNS into national sleep medicine practice, with a 2025 position paper from French sleep and ENT societies confirming Inspire IV as the only implant currently available there, restricted to non-obese patients with CPAP or oral-appliance failure. A European market-access analysis has mapped reimbursement pathways for the technology across roughly a dozen countries, including Austria, Belgium, Denmark, England, Italy, the Netherlands, Norway, Sweden, Switzerland, the Czech Republic, Finland, Hungary, and Romania, and the UK's NICE has issued its own health technology guidance evaluating HGNS for moderate-to-severe OSA, reflecting formal integration into NHS assessment pathways. Newer multicenter trials for next-generation bilateral stimulation systems have enrolled patients across sites in the United States, Europe, and Australia, signaling that the device pipeline is being validated for international rollout rather than single-market use. Adoption in Asia remains more limited and uneven; South Korea, for instance, has documented OSA prevalence data supporting the treatment's relevance but has been slower to build the implantation infrastructure seen in Western Europe and the U.S.. The overall picture is one of a maturing, multinational therapy — well established in the U.S., UK, Germany, and France, expanding across the rest of the EU and into Australia, and still in earlier stages of adoption across much of Asia, Latin America, and lower-resource health systems, largely due to cost, the need for specialized surgical infrastructure, and variable insurance or national reimbursement. 

Why This Cannot Be Done at Home

Given the appeal of electrical stimulation as a "gadget-based" fix, it's worth being explicit: HGNS is not something that can be approximated with a store-bought TENS unit or consumer neurostimulator. The therapy depends on a surgically placed electrode cuff positioned directly on the hypoglossal nerve itself, precisely timed to the individual patient's own respiratory sensor signal — not a generic muscle-stimulation pattern applied to the skin surface. Surface electrical stimulators cannot reach or selectively activate this deep cranial nerve, cannot synchronize with breathing, and cannot reproduce the directional tongue-protrusion effect that prevents airway collapse. Attempting to self-treat OSA with off-the-shelf electrostimulators offers no evidence of benefit and carries real risks — including skin injury, unpredictable muscle activation, and, most importantly, false reassurance in a condition where untreated apnea itself raises risk of stroke, heart attack, accidents, and death. Candidacy for genuine HGNS also requires specific criteria — moderate-to-severe OSA, non-obese body habitus, CPAP intolerance — that only a sleep specialist and otolaryngologist can properly assess. 

The New Cardiovascular Data: A More Complicated Picture

This context matters directly for interpreting the new findings reported by Neil Kondamuri and colleagues in JAMA Otolaryngology–Head & Neck Surgery. Using a large retrospective cohort of nearly 3,800 HGNS recipients matched against candidates who did not undergo implantation, the study found a pattern that cuts against simple optimism: within the first two years after implantation, HGNS recipients without pre-existing cardiovascular disease had a notably higher hazard of new hypertension diagnosis (HR 1.70), and among patients who already had diabetes or hypertension, HGNS recipients faced higher hazards of both minor (HR 1.44) and major (HR 1.62) cardiovascular events compared to controls. Only after two years did the picture reverse, with lower hazards of diabetes and hypertension diagnoses, and cardiovascular event hazards trending toward benefit by year three (minor events HR 0.42, major events HR 0.40).

The authors themselves called the early-period findings unexpected, since prior OSA treatments have shown blood pressure benefits within a month, and offered two plausible explanations: increased healthcare contact around device implantation and postoperative visits may simply have generated more diagnostic opportunities, or — more likely — patients selected for HGNS may have had unmeasured baseline OSA severity and cardiovascular risk that the matching process, limited by the claims database, could not fully capture.

What This Means for Patients and Clinicians

The clinical message emerging from this study is one of measured patience rather than either alarm or premature celebration. HGNS appears to offer real longer-term metabolic and cardiovascular advantages consistent with what has been seen after other surgical OSA treatments, but the early post-implantation period does not show — and may even work against — the immediate cardiovascular benefit that patients frequently cite as their primary reason for pursuing the therapy. As the study authors note, this has direct implications for how primary care physicians, sleep specialists, and otolaryngologists counsel patients: informed consent for HGNS should include realistic expectations about timeline, an understanding that cardiovascular benefit is a multi-year proposition rather than an immediate one, and continued cardiovascular monitoring — not diminished vigilance — in the first two years after implantation, particularly in patients who already carry diabetes or hypertension.

Mykola Iabluchanskyi together with Andriy Yabluchanskiy